I-01 Robert Leary QRPEM, A Quasi-Random Parametric EM Method Wednesday 10:15-11:45 |
I-02 Donghwan Lee Quantitative Analysis of Reflux Episodes in Gastroesophageal Reflux Disease (GERD) Wednesday 10:15-11:45 |
I-03 Eun-Kyung Lee Various validation methods to check the estimation methods with stochastic sampling approach Wednesday 10:15-11:45 |
I-04 Joomi Lee Population Pharmacokinetics of Sumatriptan in Healthy Korean Male Subjects Wednesday 10:15-11:45 |
I-05 Annabelle Lemenuel Diot Identification of a dual mechanism of action (MoA) for Danoprevir (DNV), a protease inhibitor currently in phase 2, using a mechanistic viral kinetic model Wednesday 10:15-11:45 |
I-06 Sergei Leonov Optimal design of population pharmacokinetic/pharmacodynamic studies Wednesday 10:15-11:45 |
I-07 Claire Li Clinical trial simulations of the anticancer agents- abiraterone and nilotinib Wednesday 10:15-11:45 |
I-08 Earvin Liang Clinical Trial Design Optimization: A Pharmacokinetic Sampling Plan for a Phase 3 Clinical Trial in Mild Alzheimer Disease Patients Wednesday 10:15-11:45 |
I-09 Floriane Lignet Computational Model of In Vitro Breast Cancer Cells Spheroid-Formation Wednesday 10:15-11:45 |
I-10 Lars Lindbom Addressing variability and uncertainty in pooled pre-clinical data improved the quality of compound selection of a gamma secretase modulator in Alzheimer’s Disease Wednesday 10:15-11:45 |
I-11 Rocio Lledo Dose escalation studies for mAb: prior distributions selection and software comparison Wednesday 10:15-11:45 |
I-13 Gaohua Lu Application of the Simcyp PBPK/PD model to Simulate PK and PD of Nifedipine in Japanese Populations Wednesday 10:15-11:45 |
I-14 James Lu Refining the mechanism of CETP mediated lipid transfer in a stochastic model of lipoprotein metabolism and kinetics (LMK model) Wednesday 10:15-11:45 |
I-15 Peiming Ma Organization of Target-Mediated Disposition (TMD) Models including Michaelis-Menten (MM), rapid-binding (RB), and quasi-steady-state (Qss) models Wednesday 10:15-11:45 |
I-16 Arianna Madrid Aispuro A Systematic Approach to PKPD Model Development to describe Sleep Effects of Compounds with Different Mechanisms of Action Using Semi-Mechanistic Markov Chain Models Wednesday 10:15-11:45 |
I-17 Victor Mangas-Sanjuan Three Compartment Model To Describe Atipical Permeability Profiles In CACO-2 Cells Wednesday 10:15-11:45 |
I-18 Mathilde Marchand How to support a definitive bioequivalence study design using modeling and simulation Wednesday 10:15-11:45 |
I-19 John Maringwa Model-based meta-analysis of summary clinical outcome data in idiopathic pulmonary fibrosis (IPF) Wednesday 10:15-11:45 |
I-20 Eleonora Marostica Second order Markov modelling of HAMD responses in depression trials Wednesday 10:15-11:45 |
I-21 Amelie Marsot Thiopental and esomeprazole in critically ill patients: Drug interaction. Wednesday 10:15-11:45 |
I-22 Silvia Illamola Population pharmacokinetics of amikacin in newborns Wednesday 10:15-11:45 |
I-23 Maria Matoses Osborne Development of a PBPK model for the anticancer drug Vivia009 and its main metabolite administered as a new delivery system in the Rat Wednesday 10:15-11:45 |
I-24 Veronese Mattia Optimal Experimental Design for receptor drug development with PET studies Wednesday 10:15-11:45 |
I-25 Christophe Meille Modified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical data Wednesday 10:15-11:45 |
I-26 Sven Mensing Evaluation of the long-term decline of platelets following Navitoclax (ABT-263) administration in Cancer Patients with a semi-physiological pharmacodynamic model Wednesday 10:15-11:45 |
I-27 François Mercier A discussion on two approaches for indirect treatment comparisons based on public-domain metadata: The case of side-effects incidence Wednesday 10:15-11:45 |
I-28 Enrica Mezzalana A Target-Mediated Drug Disposition model to quantify the relationship between Anti-CD3 monoclonal antibody and CD3/TCR receptors in Patients with autoimmune diseases. Wednesday 10:15-11:45 |
I-29 Jonathan Mochel Using nonlinear mixed effects modeling to characterize the pharmacokinetics and pharmacodynamics of benazepril in dogs. Wednesday 10:15-11:45 |
I-30 Samer Mouksassi Equivalence of locally acting drugs based on pharmacodynamic data: development of a novel 1 step method and use of trial simulations to assess sources of variability and power definitive studies Wednesday 10:15-11:45 |
I-31 Ricardo Nalda-Molina Stochastic Simulations Assist to Improve a Poorly Designed Clinical Study for the CSF Pharmacokinetics of Doripenem Wednesday 10:15-11:45 |
I-32 Carmen Navarro Computer simulations of bioequivalence trials: drugs with sequential metabolism Wednesday 10:15-11:45 |
I-33 Michael Neely Non-Parametric Bayesian Fitting: A Novel Approach to Population Pharmacokinetic Modeling Wednesday 10:15-11:45 |
I-34 Thu Thuy Nguyen Modelling the impact of fecal ciprofloxacin concentrations on fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance? Wednesday 10:15-11:45 |
I-35 Ronald Niebecker Modelling of Anti-Drug Antibodies Directed Against a Monoclonal Antibody Wednesday 10:15-11:45 |
I-36 Christoph Niederalt The use of physiologically-based pharmacokinetic modeling in the design of pH-dependent target binding antibodies Wednesday 10:15-11:45 |
I-37 Elisabet Nielsen Target Attainment Analysis to Evaluate Dosing Regimens of an Oral β-Lactam Antibioic Wednesday 10:15-11:45 |
I-38 Valerie Nock Comparison of three PK/PD models for glycated haemoglobin in diabetes type 2 patients treated with lixisenatide Wednesday 10:15-11:45 |
I-39 Yookhwan Noh Bioequivalence evaluation using population modeling method Wednesday 10:15-11:45 |
I-40 Joakim Nyberg The robustness of global optimal designs Wednesday 10:15-11:45 |
I-41 Kayode Ogungbenro A semi-mechanistic gastric emptying model for double peaks in pharmacokinetics using LDOPA data Wednesday 10:15-11:45 |
I-42 Katie Owens The Pharmacokinetic Profile of Intravenous Paracetamol in Adult Patients Undergoing Major Surgery: A Population Analysis Wednesday 10:15-11:45 |
I-43 Sung Min Park Population pharmacokinetics of S-amlodipine in healthy Korean male subjects Wednesday 10:15-11:45 |
I-45 Zinnia Parra-Guillen Tumour Growth Modelling In Immunotherapy Wednesday 10:15-11:45 |
I-46 Mélanie Pastor Modeling of the effect of G-CSF in limiting the neutropenic toxicity of carboplatin Wednesday 10:15-11:45 |
I-47 Pavan Vajjah Prediction of serum and cerebrospinal fluid concentrations of carbamazepine: An application of parameter estimation and the permeability limited 4-compartment brain model in Simcyp® Wednesday 10:15-11:45 |
I-48 Kirill Peskov Mechanistic modeling approach relating human gut microbial community to physiologically-relevant biomarkers Wednesday 10:15-11:45 |
I-49 Klas Petersson Simultaneous modeling of prolactin data following administration of seven D2–receptor antagonists in rats; Model-based in vitro – rat – human scaling Wednesday 10:15-11:45 |
I-50 Chiara Piana Non-adherence to antiretroviral combination therapy in HIV-infected children Wednesday 10:15-11:45 |
I-51 Sabine Pilari Mathematical Model of Homeostasis of Endogenous Hormones Following Hormone Replacement Therapy Wednesday 10:15-11:45 |
I-52 Venkatesh Pilla Reddy Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety Wednesday 10:15-11:45 |
I-53 Elodie Plan Bayesian Joint Modeling of Bone Mineral Density and Repeated Time-To-Fracture Event for Multiscale Bone Systems Model Extension Wednesday 10:15-11:45 |
I-54 Bart Ploeger Investigation of a Data Transformation Procedure to Improve Identifiability of Efficacy and Potency: Application to Continuous Elevated Plus-Maze Data in Rats Wednesday 10:15-11:45 |
I-55 Arnaud Quelin How Anti-cancer Targeted Therapies Used in Combination Interact? Analysis with a Semi-mechanistic Model of Minimal Signalling Networks Wednesday 10:15-11:45 |
I-56 Christian Hove Claussen Pharmacokinetics of concentrated insulin mixtures: a biosimulation approach Wednesday 10:15-11:45 |
I-57 Dinko Rekic External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients Wednesday 10:15-11:45 |
I-58 Sylvie Retout Prediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors Wednesday 10:15-11:45 |
I-59 Benjamin Ribba A model for low-grade glioma tumor growth and response to chemotherapy and radiotherapy Wednesday 10:15-11:45 |
I-60 Nikita Rodichenko Multimodal Physiologically-Based Modelling and Analysis of Kinetics of Drug-Delivery with Modular Nanotransporters (MNT) Wednesday 10:15-11:45 |
I-61 Rikke Meldgaard Røge Integrated model of glucose homeostasis including the effect of exogenous insulin Wednesday 10:15-11:45 |
I-62 Hyerang Roh Quantitative assessment of drug response in male patients with severe nocturia receiving a combined medication of solifenacin and tamsulosin Wednesday 10:15-11:45 |
I-63 Rachel Rose Prediction of the Hypnotic Effects of Zolpidem by Extrapolation of a Mechanism-Based PKPD Model Developed for Triazolam in Healthy Volunteers. Wednesday 10:15-11:45 |
I-64 Roel Straetemans Pharmacokinetic/Pharmacodynamic Simulations Of The vWF Targeting Nanobody® ALX-0081 In Pediatric Patients With TTP Wednesday 10:15-11:45 |
I-65 Amit Roy Characterization of the Occurrence, Severity, and Duration of Immune-Related Adverse Events (irAEs) in Advanced Melanoma Patients Treated with Ipilimumab Wednesday 10:15-11:45 |
I-66 Hauke Ruehs Integrated PK/PD model for oxaliplatin in different human matrices Wednesday 10:15-11:45 |
I-67 Alberto Russu A new, second-order indirect model of depression time course Wednesday 10:15-11:45 |
I-68 Vargo Ryan Comparator based dose-response model prediction of clinical irrelevance following near miss bioequivalence results for Cmax Wednesday 10:15-11:45 |
I-69 Yu-Yuan Chiu Dose-Response Model of Lurasidone Treatment in Schizophrenia Wednesday 10:15-11:45 |